Marlio Charles Mosseri Purchases 50,000 Shares of Nuvectis Pharma (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri purchased 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was bought at an average cost of $18.32 per share, with a total value of $916,000.00. Following the purchase, the insider owned 3,186,576 shares of the company’s stock, valued at $58,378,072.32. This represents a 1.59% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Nuvectis Pharma Trading Up 4.2%

Nuvectis Pharma stock traded up $0.77 during trading hours on Wednesday, reaching $19.16. 753,700 shares of the stock were exchanged, compared to its average volume of 139,201. The company has a market cap of $508.21 million, a P/E ratio of -14.57 and a beta of -0.07. Nuvectis Pharma, Inc. has a twelve month low of $5.55 and a twelve month high of $29.27. The stock has a 50 day moving average of $12.05 and a two-hundred day moving average of $9.66.

Nuvectis Pharma (NASDAQ:NVCT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. On average, analysts expect that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on NVCT. Wall Street Zen raised Nuvectis Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. HC Wainwright boosted their target price on Nuvectis Pharma from $13.00 to $39.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvectis Pharma in a report on Friday, June 5th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $39.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of Nuvectis Pharma by 3,398.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock valued at $47,000 after acquiring an additional 6,084 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Nuvectis Pharma in the second quarter valued at about $53,000. Bank of America Corp DE boosted its stake in shares of Nuvectis Pharma by 417.2% during the second quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock valued at $64,000 after purchasing an additional 6,909 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Nuvectis Pharma by 3,671.4% during the fourth quarter. Deutsche Bank AG now owns 12,672 shares of the company’s stock valued at $96,000 after purchasing an additional 12,336 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new stake in shares of Nuvectis Pharma during the second quarter worth about $97,000. 96.77% of the stock is currently owned by institutional investors.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.